ICIs can also be associated with chemotherapy agents to treat certain types of cancer: in 2019, FDA has approved the combination of atezolizumab and paclitaxel for treating patients with advanced metastatic triple negative breast cancer expressing PD-L1, without previous systemic treatment for metastatic disease (56, 57). This evidence concerns the gene CD274 and cancer.